CSL Behring recently announced that the US Food and Drug Administration (FDA) has approved Hizentra (immune globulin subcutaneous [human] 20% liquid) as the first and only subcutaneous immunoglobulin (SCIg) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment. CIDP is a rare autoimmune disorder that affects the peripheral nerves and may cause permanent nerve damage. CSL Behring is headquartered in Melbourne, Australia, and King of Prussia, PA, in the US.
Indications: Hizentra is indicated for the treatment of:
- Primary immunodeficiency (PI) in adults and pediatric patients aged ≥2 years.
- Maintenance therapy in adults with CIDP.
Dosage/administration: Hizentra is for subcutaneous infusion only. Before switching to Hizentra, physicians should obtain the patient’s serum IgG trough level to guide subsequent dose adjustments. Additional information about dosing can be found here: http://labeling.cslbehring.com/PI/US/Hizentra/EN/Hizentra-Prescribing-Information.pdf.
Adverse reactions: The most common adverse reactions observed in ≥5% of study subjects were local infusion site reactions, headache, diarrhea, fatigue, back pain, nausea, pain in extremity, cough, upper respiratory tract infection, rash, pruritus, vomiting, abdominal pain (upper), migraine, arthralgia, pain, fall and nasopharyngitis.
FDA approves Hizentra (immune globulin subcutaneous [human] 20% liquid) for the treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP). [news release]. Melbourne, Australia, and King of Prussia, PA: CSL Behring. March 16, 2018. https://www.prnewswire.com/news-releases/fda-approves-hizentra-immune-globulin-subcutaneous-human-20-liquid-for-the-treatment-of-patients-with-chronic-inflammatory-demyelinating-polyneuropathy-cidp-300615161.html. Accessed March 27, 2018.
This Week's Must Reads
Midlife Risk Factors Linked to Late-Onset Epilepsy, JAMA Neurology; ePub 2018 Jul 23; Johnson, et al
Nearly 1 Million Adults ≥55 Years Have Epilepsy, Epilepsy Behav; ePub 2018 Aug 2; Sapkota, et al
Incidental Findings Common in Stroke Patients, J Stroke Cerebrovasc Dis; ePub 2018 Aug 2; Doyle, et al
Spatial Heterogeneity of White Matter Lesions , Neurology; ePub 2018 Aug 3; Habes, et al
Poor Sleep Linked to Slow Recovery from TBI, Sleep; ePub 2018 Jul 24; Kalmbach, Conroy, et al
Must Reads in FDA Actions
FDA Approves Xeomin for Excessive Drooling, Merz North America news release; 2018 Jul 3
FDA Approves Epidiolex for Rare Epilepsy Forms, FDA news release: 2018 Jun 25
FDA Approves Medtronic’s DBS Therapy for Epilepsy, Medtronic news release; 2018 May 1
FDA Approves Expanded Use of Exparel Nerve Block, Pacira news release; 2018 Apr 6
FDA Approves Hizentra for CIDP Treatment, CSL Behring news release; 2018 Mar 16